“An Oral, Selective Tyrosine Kinase 2 Inhibitor, BMS-986165, Reduced Absolute Psoriasis Area and Severity Index in a Phase 2 Trial in Psoriasis”. SKIN The Journal of Cutaneous Medicine 4, no. 5 (September 2, 2020): s27. Accessed April 19, 2025. https://skin.dermsquared.com/skin/article/view/976.